Symbole graficzne aparatów, maszyn i urządzeń przemysłu chemicznego
Antineoplastics
1
Reactions 1223 - 11 Oct 2008 S Antineoplastics Fatal reactivation of hepatitis B virus infection: case report A 21-year-old woman developed fatal reactivation of hepatitis B viral infection during treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone for mediastinal large B cell lymphoma. The woman started receiving rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone [dosages not stated] and, after the fourth cycle, had improvement in her mediastinal mass size. After 2 weeks, she presented with nausea and vomiting. Her serum transaminase levels were more than 10 times the upper limit of normal [duration of treatment to reaction onset not stated]. At this time, she reported a history of transient childhood jaundice. Over the next 3 days, her transaminase levels continued to increase and she developed jaundice and coagulation disorders. She tested positive for hepatis B surface antigen and e antibody. Hepatitis B core antibody was IgM negative and IgG positive and her hepatitis B DNA level was 4.522 × 10 8 IU/mL. Analysis of her serum sample from before chemotherapy initiation was positive for hepatitis B surface antigen and negative for e antigen, which suggested chronic infection with a precore stop-codon variant. The woman started receiving lamivudine. However, she developed fulminant liver failure, encephalopathy, sepsis, renal failure, acute lung injury and uncontrolled haemorrhage. She received full supportive care in an ICU, but died after 1 week. Dillon R, et al. Fatal reactivation of hepatitis B after chemotherapy for lymphoma. BMJ 337: 756-758, No. 7672, 27 Sep 2008 - England 801020634 1 Reactions 11 Oct 2008 No. 1223 0114-9954/10/1223-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
Transcript of Antineoplastics
Reactions 1223 - 11 Oct 2008
SAntineoplastics
Fatal reactivation of hepatitis B virus infection: casereport
A 21-year-old woman developed fatal reactivation ofhepatitis B viral infection during treatment with rituximab,cyclophosphamide, doxorubicin, vincristine and prednisolonefor mediastinal large B cell lymphoma.
The woman started receiving rituximab, cyclophosphamide,doxorubicin, vincristine and prednisolone [dosages not stated]and, after the fourth cycle, had improvement in hermediastinal mass size. After 2 weeks, she presented withnausea and vomiting. Her serum transaminase levels weremore than 10 times the upper limit of normal [duration oftreatment to reaction onset not stated]. At this time, shereported a history of transient childhood jaundice. Over thenext 3 days, her transaminase levels continued to increase andshe developed jaundice and coagulation disorders. She testedpositive for hepatis B surface antigen and e antibody.Hepatitis B core antibody was IgM negative and IgG positiveand her hepatitis B DNA level was 4.522 × 108 IU/mL. Analysisof her serum sample from before chemotherapy initiation waspositive for hepatitis B surface antigen and negative fore antigen, which suggested chronic infection with a precorestop-codon variant.
The woman started receiving lamivudine. However, shedeveloped fulminant liver failure, encephalopathy, sepsis,renal failure, acute lung injury and uncontrolled haemorrhage.She received full supportive care in an ICU, but died after1 week.Dillon R, et al. Fatal reactivation of hepatitis B after chemotherapy for lymphoma.BMJ 337: 756-758, No. 7672, 27 Sep 2008 - England 801020634
1
Reactions 11 Oct 2008 No. 12230114-9954/10/1223-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
